Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Upgraded by StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday.

Other analysts also recently issued reports about the stock. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research report on Monday, November 25th.

Abeona Therapeutics Trading Down 0.7 %

Abeona Therapeutics stock opened at $5.57 on Tuesday. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $242.13 million, a price-to-earnings ratio of -2.07 and a beta of 1.44. The firm has a 50-day moving average price of $6.02 and a two-hundred day moving average price of $5.59.

Institutional Investors Weigh In On Abeona Therapeutics

Large investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at $84,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Abeona Therapeutics in the third quarter worth about $151,000. XTX Topco Ltd purchased a new position in shares of Abeona Therapeutics in the third quarter worth approximately $160,000. JPMorgan Chase & Co. raised its holdings in shares of Abeona Therapeutics by 74.2% during the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after acquiring an additional 28,606 shares during the period. Finally, GSA Capital Partners LLP lifted its position in shares of Abeona Therapeutics by 54.3% in the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after acquiring an additional 33,831 shares in the last quarter. 80.56% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.